Lot, batch & COA requirements

When you buy from a research vendor rather than a licensed pharmaceutical manufacturer, trust alone is not a quality system—identification testing is.

Identification testing confirms the molecular identity of the peptide. It does not measure purity or how much is in the vial. It answers one question: is this the correct compound?

The most common approach is mass spectrometry, often LC-MS (liquid chromatography–mass spectrometry).

Every molecule has a precise molecular mass, measured in daltons (atomic-scale mass units).

In a mass spectrometer, the sample is ionized and fragmented; the instrument measures mass-to-charge ratios. The resulting pattern is compared to the expected pattern for the labeled peptide.

A match supports that the sample is the claimed compound. A mismatch suggests mislabeling, substitution, or a synthesis error.

Without identification testing, there is no objective check that the vial matches the label.

Identification is the baseline: other tests (purity, content, sterility) are only meaningful if the compound was identified correctly first.

Often listed as “Identification” with “Conforms,” “Pass,” or similar, and a method such as LC-MS or MS. A conforming result means the observed profile matched the expected identity for that product.

Net content (also called assay or peptide content) is the quantity of peptide in the vial or sample, often expressed as a percentage of label claim—for example 98% means 98% of the labeled amount.

Peptides are often supplied as salts (for example TFA or acetate forms). The counterion has mass and is part of the solid.

A label may state total mass including salt, while “net peptide content” refers to the active peptide mass. The difference can be meaningful depending on peptide and salt form.

A common approach is HPLC (high-performance liquid chromatography) with quantitative comparison to a certified reference standard.

The sample is separated on a column; the target peptide produces a chromatographic peak. Peak response is compared to a standard of known concentration to estimate how much peptide is present relative to the claim.

If research work relies on label claim for amount, under- or over-filling relative to claim affects experimental planning. COAs that clearly separate net peptide content from gross mass are easier to interpret.

Look for “Net Content,” “Assay,” or “Peptide Content.” Results near 95–105% of label claim are commonly seen as acceptable bands in industry discussions; values far outside that range deserve scrutiny.

Identification confirms which compound is present. Net content addresses how much. Net purity describes how much of the measured material is the target peptide versus everything else—related sequences, byproducts, fragments, and other impurities.

It is usually reported as a percentage: 98% purity means roughly 98% of the integrated signal (by the stated method) is attributed to the target peptide.

Solid-phase peptide synthesis builds chains stepwise; incomplete coupling can yield truncated sequences. Other impurities may include deletion sequences, oxidized residues, aggregates, or residual reagents.

HPLC is primary: the chromatogram is integrated for all peaks. The main peak is the target peptide; other peaks are impurities.

Purity is often calculated as the main peak area divided by the sum of all peak areas. Some workflows use UV at 214 nm to emphasize peptide bonds across residues.

Lower purity means more non-target material; some impurities may be biologically active, others inert. For research-use products, 98%+ net purity is a widely cited expectation when methods are comparable; always read the COA method and limits.

Listed as “Purity” or “Net Purity” with a percent and method (often HPLC or RP-HPLC). For research peptides, results below 98% warrant scrutiny—confirm with the full report and method.

An endotoxin is not intact bacteria. It is a toxic component from the outer wall of Gram-negative bacteria—often lipopolysaccharide (LPS) released when cells break apart. The immune system responds strongly to LPS.

The common method is LAL (Limulus amebocyte lysate), a reagent system sensitive to LPS, often reported in endotoxin units per mg or per mL (EU/mg, EU/mL).

Some laboratories use rFC (recombinant Factor C) or other alternatives that target the same biology with different reagent sourcing.

A sample can be “sterile” (no growth in a sterility test) and still contain endotoxin. That is why sterility and endotoxin are different COA lines.

“Endotoxins” or “Bacterial endotoxins” with a numeric result and limit. Interpretation depends on the stated acceptance criteria for that product.

Sterility testing looks for viable microorganisms—bacteria (aerobic and anaerobic), yeast, and mold—in the tested portion of the sample.

Direct inoculation: sample (or extract) is added to growth media and incubated, often including aerobic and anaerobic conditions.

Membrane filtration: sample is filtered; the filter is transferred to media and incubated—useful when the matrix inhibits growth until diluted or removed.

Sterility is performed on a sample, not the entire batch. “No growth” means none was detected under the method and incubation period for that sample—not a guarantee for every unit in the lot.

Sterility is most informative alongside controlled manufacturing, filtration strategy, and endotoxin data.

“Sterility” with Pass / No growth and a cited method (for example USP <71> or equivalent). Incubation duration (often 14 days for classical methods) should be stated in the report.

This category addresses elemental contaminants—often lead, arsenic, cadmium, mercury, and sometimes others such as nickel, chromium, or catalyst residues (for example palladium)—against specification limits.

ICP-MS (inductively coupled plasma mass spectrometry) is widely used: the matrix is atomized/ionized in a plasma; masses are separated and quantified at very low levels (often ppb or below). ICP-OES is an alternative optical technique.

Elemental contamination is a chemical manufacturing issue, not a biological growth issue. A product can pass microbial tests yet still fail elemental limits if process chemistry introduced metals.

“Heavy metals” or “elemental impurities” with per-element results in ppm or ppb. Limits are often discussed with reference frameworks such as USP <232> and ICH Q3D in regulated contexts; the COA should state the limits that apply to that release.

Identification, net content, net purity, endotoxin, sterility, and heavy metals are often run on one representative sample from a lot. That proves the tested sample met criteria at that time.

Conformity testing (as used here) refers to checking multiple vials from the same lot for consistency—typically identification, net content, and net purity across pulls—to see whether results cluster within expectations or show outliers.

Filling and finishing can introduce vial-to-vial variation. A single COA cannot reveal uneven filling or localized contamination affecting only part of a batch.

Multiple data points for the same lot—either on an extended report or separate conformity summary—showing more than one vial tested for identity, content, and purity.